Program Schedule

1150
The Disease Burden of Chronic Hepatitis C in Turkey

Session: Poster Abstract Session: Viral Infections: Epidemiology
Friday, October 10, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background: Hepatitis C virus (HCV) disease burden and the impact of new potent direct acting antivirals (DAAs) in Turkey are currently unknown. We examined HCV-related disease progression to quantify the burden of disease from a Turkish perspective.

Methods: Using a modeling approach, we quantified the HCV-infected population and associated disease progression through 2030. The HCV-infested population was characterized using published literature, Turkish government reports including year-end 2013 and estimates from a panel of country experts. We developed three treatment strategies to analyze the changes in burden of HCV infection: treatment of patients >F3 with new DAAs (restricted treatment), treatment of all patients with new DAAs (unrestricted treatment) and increased diagnosis and treatment for the elimination of HCV.

Results:

The viremic prevalence is estimated to have peaked in 1998 (601,000 individuals), and to decline 40.2% by 2030 (359,000 cases). However, the number of cases of compensated (n=74,500) and decompensated (n=9.480) cirrhosis, HCC (n=4,170), and liver-related deaths (n=3,670) will peak between 2028-2032.

Compared to the base case, under restricted treatment HCV related mortality will decrease 7% by 2030. Under unrestricted treatment, HCV related mortality will decrease 22% by 2030. Elimination was achieved through aggressive treatment and diagnosis wherein mortality was decreased by 77%.

Conclusion:

Prevalence of HCV infection in Turkey has been declining for the last 15 years; however, the prevalence of HCV-related liver disease, morbidity and mortality is increasing. This analysis may facilitate the development of strategies for HCV care and management in Turkey.

Ramazan Idilman, Gastroenterology, Ankara University School of Medicine, Ankara, Turkey

Disclosures:

R. Idilman, None

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek